Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in multiple scientific conferences during December 2024. The company will present at the Piper Sandler Healthcare Conference (Dec 3) and Evercore ISI HealthCONx Conference (Dec 4). Notable presentations include the PALISADE Phase 3 study results of plozasiran for Familial Chylomicronemia Syndrome at several events, including the APA/JPS/CAP/IAP Joint Meeting and WCIRDC.
The company will also present research on siRNA for neurodegenerative disorders and complement-targeted therapies at the RNA at the Bench and Bedside IV and Complement-Based Drug Development Summit respectively.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha annunciato la sua partecipazione a diverse conferenze scientifiche durante dicembre 2024. L'azienda presenterà alla Piper Sandler Healthcare Conference (3 dicembre) e alla Evercore ISI HealthCONx Conference (4 dicembre). Le presentazioni di rilievo includono i risultati dello studio PALISADE di Fase 3 di plozasiran per la Sindrome da Chilomicronemia Familiare in diversi eventi, tra cui il Congresso Congiunto APA/JPS/CAP/IAP e il WCIRDC.
L'azienda presenterà anche ricerche su siRNA per disturbi neurodegenerativi e terapie mirate al complemento presso il RNA at the Bench and Bedside IV e il Complement-Based Drug Development Summit rispettivamente.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) ha anunciado su participación en múltiples conferencias científicas durante diciembre de 2024. La empresa presentará en la Piper Sandler Healthcare Conference (3 de diciembre) y en la Evercore ISI HealthCONx Conference (4 de diciembre). Entre las presentaciones destacadas se incluyen los resultados del estudio PALISADE de Fase 3 de plozasiran para el Síndrome de Quilomicronemia Familiar en varios eventos, incluyendo la Reunión Conjunta APA/JPS/CAP/IAP y el WCIRDC.
La empresa también presentará investigaciones sobre siRNA para trastornos neurodegenerativos y terapias dirigidas al complemento en el RNA at the Bench and Bedside IV y el Complement-Based Drug Development Summit respectivamente.
Arrowhead Pharmaceuticals (NASDAQ: ARWR)는 2024년 12월에 여러 과학 회의에 참여할 것이라고 발표했습니다. 이 회사는 Piper Sandler Healthcare Conference (12월 3일)와 Evercore ISI HealthCONx Conference (12월 4일)에서 발표할 예정입니다. 주목할 만한 발표로는 plozasiran의 Familial Chylomicronemia Syndrome에 대한 PALISADE 3상 연구 결과가 있으며, 이 결과는 APA/JPS/CAP/IAP 합동회의와 WCIRDC를 포함한 여러 행사에서 발표될 예정입니다.
이 회사는 또한 신경퇴행성 질환에 대한 siRNA 연구와 보완 타겟 요법에 대한 연구를 각각 RNA at the Bench and Bedside IV 및 Complement-Based Drug Development Summit에서 발표할 것입니다.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) a annoncé sa participation à plusieurs conférences scientifiques en décembre 2024. L'entreprise présentera à la Piper Sandler Healthcare Conference (3 décembre) et à la Evercore ISI HealthCONx Conference (4 décembre). Parmi les présentations notables, on trouve les résultats de l'étude de phase 3 PALISADE concernant plozasiran pour le syndrome de chylomicronémie familiale lors de plusieurs événements, y compris la réunion conjointe APA/JPS/CAP/IAP et le WCIRDC.
L'entreprise présentera également des recherches sur le siRNA pour les troubles neurodégénératifs et des thérapies ciblées sur le complément lors de la conférence RNA at the Bench and Bedside IV et du Complement-Based Drug Development Summit respectivement.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) hat seine Teilnahme an mehreren wissenschaftlichen Konferenzen im Dezember 2024 angekündigt. Das Unternehmen wird auf der Piper Sandler Healthcare Conference (3. Dezember) und der Evercore ISI HealthCONx Conference (4. Dezember) präsentieren. Bedeutende Präsentationen umfassen die Ergebnisse der PALISADE Phase 3-Studie zu plozasiran für das familiäre Chylomikronämiesyndrom bei mehreren Veranstaltungen, einschließlich des gemeinsamen Treffens APA/JPS/CAP/IAP und des WCIRDC.
Das Unternehmen wird auch Forschung zu siRNA bei neurodegenerativen Erkrankungen und komplementärgerichteten Therapien auf dem RNA at the Bench and Bedside IV und dem Complement-Based Drug Development Summit präsentieren.
- None.
- None.
Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024
Type: Fireside Chat Presentation
Date/Time: December 3, 2024, 1:30 p.m. EST
7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024
Type: Fireside Chat Presentation
Date/Time: December 4, 2024, 2:10 p.m. EST
The APA/JPS/CAP/IAP 2024 Joint Meeting – December 9-12, 2024
Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time: December 9, 2024, 12:00 p.m. HST
Presenter: Eleonora Goldberg
Session: Poster
RNA at the Bench and Bedside IV – December 9-11, 2024
Title: Developing siRNA for Neurodegenerative Disorders
Date/Time: December 9, 2024, 2:10 p.m. PST
Presenter: Christine Esau
Session: Pre-clinical RNA Therapeutics
21st Global CVCT Forum – December 9-11, 2024
Title: A Randomized, Placebo-Controlled Phase 3 Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
Date/Time: December 10, 2024, 7:30 p.m. EST
Presenter: Jennifer Hellawell and Robert Rosenson
Session: Attended Poster Viewing Session and Oral Presentation
8th Complement-Based Drug Development Summit – December 10-11, 2024
Title: Targeting Complement C3 and Factor B with siRNA: Concept to Clinic
Date/Time: December 11, 2024, 10:00 a.m. EST
Presenter: James Hamilton
Session: Advancing Complement Therapies: Pathways, Clinical Insights & Future Directions
22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) – December 12-14, 2024
Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time: December 13, 2024, 7:30-9:00 a.m. PST
Presenter: Nick Leeper and Ira Goldberg
Session: Poster and Abstract Oral Presentation Session
Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202655432/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
What conferences will Arrowhead Pharmaceuticals (ARWR) attend in December 2024?
What will Arrowhead Pharmaceuticals (ARWR) present about plozasiran in December 2024?
When is Arrowhead's (ARWR) presentation at the Piper Sandler Healthcare Conference?
